Morphological Changes in Parkinson's Disease Using Nuclear Magnetic Resonance
October 2022
in “
Amplla Editora eBooks
”
Related Community Posts Join
6 / 1000+ resultscommunity Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia.
in Research/Science 13 upvotes 1 year ago A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
community HMI 115 hasn't done phase one yet for AGA?
in Research/Science 6 upvotes 3 years ago User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community MY ANECDOTAL REPORT ON SAFETY OF ALFATRADIOL AND FLURIDIL COMBINED WITH FINASTERIDE! COMPOUNDS APPROVED FOR MPB IN THE EUROPEAN UNION (i cant comment on the efficacy, cause i am on other treatments)
in Treatment 9 upvotes 3 years ago The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
in Chat 30 upvotes 1 month ago PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Amplifica and AMP-303 clinical phase 1
in Research/Science 8 upvotes 2 years ago Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community PP405 (Non) Update - Feb 2025
in Research/Science 34 upvotes 1 year ago The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Similar Research
5 / 1000+ resultsresearch USO DE ESTIMULAÇÃO CEREBRAL PROFUNDA (DBS) PARA O TRATAMENTO DA DOENÇA DE PARKINSON
October 2022 in “Amplla Editora eBooks” Deep Brain Stimulation helps manage Parkinson's symptoms when medication isn't enough.
research Efeitos da fotobiomodulação no estresse oxidativo e seu impacto sobre a atrofia muscular por desnervação
May 2020research LATERALIZAÇÃO DO NERVO ALVEOLAR INFERIOR COMO ALTERNATIVA A INSTALAÇÃO DE IMPLANTES OSSEOINTEGRADOS NA REGIÃO POSTERIOR DA MANDÍBULA
October 2023research ADVANCES IN FUNCTIONAL NEUROSURGERY – MACHINE LEARNING, NEURAL ENGINEERING AND ROBOTICS IN TREATMENT OF NEURODEGENERATIVE DISORDERS
January 2024 in “Wiadomości Lekarskie” AI and robotics are improving treatment and monitoring of neurodegenerative disorders like Parkinson's.